查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1744581

2032 年功效測試市場預測：按產品類型、測試類型、方法、最終用戶和地區進行的全球分析

Efficacy Testing Market Forecasts to 2032 - Global Analysis By Product Type (Pharmaceuticals, Cosmetics, Medical Devices and Other Product Types), Test Type, Method, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球功效測試市場預計在 2025 年達到 5.149 億美元，到 2032 年將達到 9.055 億美元，預測期內的複合年成長率為 8.4%。

功效測試是對產品性能進行科學評估的過程，以確定其在特定條件下達到預期效果的能力。它涉及透過受控實驗來評估產品如何有效地實現其聲稱的功能，例如控制病蟲害或促進農業生長。此類測試對於檢驗產品聲明、確保合規性以及指導使用方法至關重要。功效測試提供了支援產品認證的關鍵數據，有助於配方改進，並透過已證實的功效建立了使用者信任。

根據美國食品藥物管理局（FDA）的數據，2022年至2023年間，因功效或安全性問題而召回的產品數量將增加15％，這促使企業進一步投資於嚴格的測試通訊協定。

日益嚴格的監管合規要求

嚴格的全球監管標準迫使製藥和生技公司透過全面的功效測試來檢驗其產品功效。 FDA 和 EMA 等監管機構在產品核准前越來越重視產品功效。各公司正增加對完善功效測試程序的投資，以降低產品召回和合規性問題的風險。臨床試驗和非臨床試驗透明度和課責的提高也強化了這一趨勢。因此，功效測試服務正逐漸成為產品開發週期中不可或缺的一部分。

先進測試設備高成本

採用先進的功效測試技術需要大量的資本投入，這限制了中小企業的可近性。影像系統、高通量篩檢平台和分子檢測等設備高昂的採集費用構成了財務限制。這種成本密集型環境阻礙了市場擴張，尤其是在研發預算有限的新興經濟體。預算限制通常會延遲測試階段並延長產品開發週期。透過技術創新和租賃模式解決成本障礙，有助於擴大市場滲透。

個人化醫療和生物技術的成長

個人化治療方法的加速普及需要根據特定患者情況進行精準的療效測試。各公司正專注於生物標記檢驗和伴隨診斷，以準確評估治療反應。這種轉變為療效測試提供者提供了實現服務多元化的巨大機會。生物製藥領域研發投入的不斷增加以及臨床試驗數量的不斷成長進一步加速了這一趨勢。客製化化療效評估正逐漸成為下一代療法競爭格局中的關鍵差異化因素。

對傳統測試模式的倫理擔憂

動物試驗和人體功效測試模型通常需要接受倫理審查，這可能會阻礙研究核准。未能解決這些倫理挑戰可能會導致法律糾紛，並損害檢測實驗室的聲譽。對符合倫理規範的實踐的需求正推動產業向試管內和計算模型發展。此外，全球倫理指南的協調並不一致，這帶來了進一步的合規挑戰。這項威脅要求創新倫理測試通訊協定，並與相關人員進行透明的溝通。

COVID-19的影響：

此次疫情凸顯了功效測試在縮短疫苗和療法研發週期方面的關鍵作用。快速檢測通訊協定和緊急核准增加了在壓縮時限內取得可靠功效數據的需求。這場危機也凸顯了遠端和自動化測試解決方案對於確保業務永續營運連續性的重要性。從長遠來看，新冠疫情已導致功效測試能力的資金籌措和基礎設施升級。預計這種轉變將在疫情直接影響後維持市場成長。

預計製藥業將成為預測期內最大的產業

由於整個藥物開發過程都依賴嚴格的驗證方案，預計製藥業將在預測期內佔據最大的市場佔有率。監管部門對療效的證明要求也進一步促進了該行業的成長。隨著針對慢性病和文明病的藥物數量不斷增加，製藥公司正在加大對療效研究的投資。此外，製藥公司與合約研究組織 (CRO) 之間的合作正在簡化大規模試驗的流程。該行業在確保監管部門核准和市場准入方面發揮戰略性作用，從而鞏固了主導地位。

預計體外測試部分在預測期內將以最高的複合年成長率成長。

體外檢測領域預計將在預測期內實現最高成長，因為它能夠提供準確的結果，且無需擔心動物試驗相關的倫理問題。器官晶片和3D細胞培養技術的創新使體外檢測更加可靠且擴充性。個人化醫療的轉變將進一步推動對患者特異性體外檢測方法的需求。監管部門對替代檢測模式的支持也推動了其更廣泛的應用。從傳統的體內方法向體外平台的轉變也推動了該領域的快速擴張。

比最大的地區

由於製藥生產和研發活動蓬勃發展，預計亞太地區將在預測期內佔據最大的市場佔有率。生物技術投資的不斷增加以及政府的積極舉措正在培育一個蓬勃發展的測試生態系統。中國、印度和韓國等國家正成為療效測試服務的主要外包中心。此外，全球製藥公司紛紛在亞洲設立研發中心，也進一步鞏固了該地區的市場地位。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率，這得益於其先進的醫療基礎設施和強力的法律規範。臨床研究和精準醫療計畫資金的增加將進一步推動市場擴張。美國和加拿大主要市場參與企業和合約研究組織 (CRO) 的存在增強了該地區的競爭力。此外，對倫理試驗模式和數位化研究平台的日益重視也推動了相關技術的採用。北美快速整合技術進步的能力確保了其作為高成長地區的地位。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球功效測試市場（依產品類型）

  • 製藥
  • 化妝品
  • 醫療設備
  • 其他產品類型

6. 全球功效測試市場（依測試類型）

  • 抗菌和防腐效果測試
    • 快速檢測方法
    • 常規測試方法
  • 消毒劑功效測試
    • 表面測試方法
    • 懸浮液測試方法

7. 全球功效測試市場（依方法）

  • 體外測試
  • 體內測試
  • 臨床試驗
  • 體外研究
  • 其他方法

8. 全球功效測試市場（按最終用戶）

  • 醫院和臨床實驗室
  • 受託研究機構（CRO）
  • 農藥公司
  • 化妝品製造商
  • 其他最終用戶

9. 全球功效測試市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • 3M Group
  • Abbott Analytical
  • Accugen Laboratories, Inc.
  • Almac Group
  • ALS Limited
  • Betco
  • Bioscience Laboratories, Inc.
  • Blutest Laboratories Limited
  • Cantel Medical Corporation
  • SGS SA
  • Steris plc
  • Diversey, Inc.
  • Ecolab Inc.
  • Eurofins Scientific
  • Lucideon
Product Code: SMRC29629

According to Stratistics MRC, the Global Efficacy Testing Market is accounted for $514.9 million in 2025 and is expected to reach $905.5 million by 2032 growing at a CAGR of 8.4% during the forecast period. Efficacy testing is the process of scientifically assessing the performance of a product to determine its ability to achieve intended results under specified conditions. It involves controlled experiments to evaluate how effectively a product performs its claimed function, such as controlling pests, diseases, or enhancing growth in agriculture. This testing is essential for validating product claims, ensuring regulatory compliance, and guiding application practices. Efficacy testing provides critical data that supports product approval, helps refine formulations, and builds user confidence through proven effectiveness.

According to the US Food and Drug Administration (FDA), the number of products recalls due to inefficacy or safety concerns rose by 15% between 2022 and 2023, prompting companies to invest more in rigorous testing protocols.

Market Dynamics:

Driver:

Increasing regulatory compliance requirements

Stringent global regulatory standards are compelling pharmaceutical and biotech companies to validate the effectiveness of their products through comprehensive efficacy testing. Regulatory bodies such as the FDA and EMA have heightened their focus on product efficacy before approval. Companies are increasingly investing in robust efficacy testing procedures to mitigate the risk of product recalls or compliance issues. Enhanced transparency and accountability in clinical and non-clinical trials are reinforcing this trend. Consequently, efficacy testing services are gaining prominence as essential components of product development cycles.

Restraint:

High cost of advanced testing equipment

The adoption of sophisticated efficacy testing technologies entails significant capital investments, limiting their accessibility for small and medium enterprises. High acquisition and maintenance costs associated with equipment such as imaging systems, high-throughput screening platforms, and molecular assays pose financial constraints. This cost-intensive environment can hinder market expansion, particularly in emerging economies with limited R&D budgets. Budget constraints often result in delayed testing phases and extended product timelines. Addressing cost barriers through technological innovation and leasing models could support broader market penetration.

Opportunity:

Growth in personalized medicine and biotechnology sectors

The accelerating adoption of personalized treatment approaches necessitates precise efficacy testing tailored to specific patient profiles. Companies are focusing on biomarker validation and companion diagnostics to evaluate therapeutic responses accurately. This shift is generating substantial opportunities for efficacy testing providers to diversify service offerings. The rising R&D investments in biopharma and increasing clinical trial volumes further amplify this trend. Tailored efficacy evaluations are emerging as a critical differentiator in the competitive landscape of next-gen therapeutics.

Threat:

Ethical concerns over traditional testing models

Efficacy testing models involving animal trials and human subjects often attract ethical scrutiny, potentially hampering study approvals. Failure to address these ethical challenges may lead to legal complications and reputational damage for testing organizations. The demand for ethically sound practices is pushing the industry toward in vitro and computational models. Moreover, global harmonization of ethical guidelines is inconsistent, creating additional compliance challenges. This threat necessitates innovation in ethical testing protocols and transparent communication with stakeholders.

Covid-19 Impact:

The pandemic underscored the critical role of efficacy testing in accelerating vaccine and therapeutic development timelines. Rapid testing protocols and emergency authorizations heightened the demand for reliable efficacy data within compressed timeframes. The crisis also emphasized the importance of remote and automated testing solutions to ensure business continuity. Long-term, COVID-19 has led to increased funding and infrastructure upgrades for efficacy testing capabilities. This shift is expected to sustain market growth beyond the immediate pandemic impact.

The pharmaceuticals segment is expected to be the largest during the forecast period

The pharmaceuticals segment is expected to account for the largest market share during the forecast period, due to its reliance on rigorous validation protocols throughout drug development. Regulatory obligations to demonstrate therapeutic effectiveness further contribute to segmental growth. With an increasing number of drugs targeting chronic and lifestyle diseases, pharmaceutical companies are intensifying investments in efficacy research. Additionally, collaborations between pharma firms and CROs are streamlining large-scale testing initiatives. The segment's strategic role in ensuring regulatory approval and market entry solidifies its leadership position.

The in vitro testing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the In vitro testing segment is predicted to witness the highest growth rate, due to its ability to deliver accurate results without ethical concerns related to animal testing. Innovations in organ-on-chip and 3D cell culture technologies are enhancing in vitro testing reliability and scalability. The shift toward personalized medicine further boosts demand for patient-specific in vitro assays. Regulatory support for alternative testing models is also encouraging broader adoption. The ongoing transition from traditional in vivo approaches to in vitro platforms will continue driving this segment's rapid expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to robust pharmaceutical manufacturing and R&D activities. Growing investments in biotechnology, coupled with favorable government initiatives, are fostering a thriving testing ecosystem. Countries such as China, India, and South Korea are emerging as major outsourcing hubs for efficacy testing services. Additionally, the influx of global pharmaceutical companies establishing R&D centers in Asia further strengthens its market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by advanced healthcare infrastructure and strong regulatory oversight. Increasing funding for clinical research and precision medicine programs is further accelerating market expansion. The presence of key market players and CROs in the U.S. and Canada adds to regional competitiveness. Additionally, the growing emphasis on ethical testing models and digitized research platforms is boosting adoption. North America's ability to rapidly integrate technological advancements secures its status as a high-growth region.

Key players in the market

Some of the key players in Efficacy Testing Market include 3M Group, Abbott Analytical, Accugen Laboratories, Inc., Almac Group, ALS Limited, Betco, Bioscience Laboratories, Inc., Blutest Laboratories Limited, Cantel Medical Corporation, SGS SA, Steris plc, Diversey, Inc., Ecolab Inc., Eurofins Scientific, and Lucideon.

Key Developments:

In May 2025, SGS SA introduced an advanced efficacy testing service for antimicrobial coatings, designed for industrial and healthcare applications. The service uses AI-driven analytics to provide rapid and accurate results, ensuring compliance with global regulatory standards.

In April 2025, Eurofins Scientific launched a new high-throughput efficacy testing platform for disinfectants, targeting municipal water treatment facilities. The platform reduces testing time by 30% while maintaining precision for regulatory compliance.

In February 2025, Steris plc introduced a novel efficacy testing protocol for sterilization products, utilizing automated systems to enhance accuracy and speed in validating disinfectant performance for healthcare settings.

Product Types Covered:

  • Pharmaceuticals
  • Cosmetics
  • Medical Devices
  • Other Product Types

Test Types Covered:

  • Antimicrobial/Preservative Efficacy Testing
  • Disinfectant Efficacy Testing

Methods Covered:

  • In Vitro Testing
  • In Vivo Testing
  • Clinical Trials
  • Ex Vivo Testing
  • Other Methods

End Users Covered:

  • Hospitals & Clinical Laboratories
  • Contract Research Organizations (CROs)
  • Agrochemical Companies
  • Cosmetic Manufacturers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Efficacy Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Pharmaceuticals
  • 5.3 Cosmetics
  • 5.4 Medical Devices
  • 5.5 Other Product Types

6 Global Efficacy Testing Market, By Test Type

  • 6.1 Introduction
  • 6.2 Antimicrobial/Preservative Efficacy Testing
    • 6.2.1 Rapid Test Method
    • 6.2.2 Traditional Test Method
  • 6.3 Disinfectant Efficacy Testing
    • 6.3.1 Surface Test Method
    • 6.3.2 Suspension Test Method

7 Global Efficacy Testing Market, By Method

  • 7.1 Introduction
  • 7.2 In Vitro Testing
  • 7.3 In Vivo Testing
  • 7.4 Clinical Trials
  • 7.5 Ex Vivo Testing
  • 7.6 Other Methods

8 Global Efficacy Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinical Laboratories
  • 8.3 Contract Research Organizations (CROs)
  • 8.4 Agrochemical Companies
  • 8.5 Cosmetic Manufacturers
  • 8.6 Other End Users

9 Global Efficacy Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 3M Group
  • 11.2 Abbott Analytical
  • 11.3 Accugen Laboratories, Inc.
  • 11.4 Almac Group
  • 11.5 ALS Limited
  • 11.6 Betco
  • 11.7 Bioscience Laboratories, Inc.
  • 11.8 Blutest Laboratories Limited
  • 11.9 Cantel Medical Corporation
  • 11.10 SGS SA
  • 11.11 Steris plc
  • 11.12 Diversey, Inc.
  • 11.13 Ecolab Inc.
  • 11.14 Eurofins Scientific
  • 11.15 Lucideon

List of Tables

  • Table 1 Global Efficacy Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Efficacy Testing Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Efficacy Testing Market Outlook, By Pharmaceuticals (2024-2032) ($MN)
  • Table 4 Global Efficacy Testing Market Outlook, By Cosmetics (2024-2032) ($MN)
  • Table 5 Global Efficacy Testing Market Outlook, By Medical Devices (2024-2032) ($MN)
  • Table 6 Global Efficacy Testing Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 7 Global Efficacy Testing Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 8 Global Efficacy Testing Market Outlook, By Antimicrobial/Preservative Efficacy Testing (2024-2032) ($MN)
  • Table 9 Global Efficacy Testing Market Outlook, By Rapid Test Method (2024-2032) ($MN)
  • Table 10 Global Efficacy Testing Market Outlook, By Traditional Test Method (2024-2032) ($MN)
  • Table 11 Global Efficacy Testing Market Outlook, By Disinfectant Efficacy Testing (2024-2032) ($MN)
  • Table 12 Global Efficacy Testing Market Outlook, By Surface Test Method (2024-2032) ($MN)
  • Table 13 Global Efficacy Testing Market Outlook, By Suspension Test Method (2024-2032) ($MN)
  • Table 14 Global Efficacy Testing Market Outlook, By Method (2024-2032) ($MN)
  • Table 15 Global Efficacy Testing Market Outlook, By In Vitro Testing (2024-2032) ($MN)
  • Table 16 Global Efficacy Testing Market Outlook, By In Vivo Testing (2024-2032) ($MN)
  • Table 17 Global Efficacy Testing Market Outlook, By Clinical Trials (2024-2032) ($MN)
  • Table 18 Global Efficacy Testing Market Outlook, By Ex Vivo Testing (2024-2032) ($MN)
  • Table 19 Global Efficacy Testing Market Outlook, By Other Methods (2024-2032) ($MN)
  • Table 20 Global Efficacy Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Efficacy Testing Market Outlook, By Hospitals & Clinical Laboratories (2024-2032) ($MN)
  • Table 22 Global Efficacy Testing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 23 Global Efficacy Testing Market Outlook, By Agrochemical Companies (2024-2032) ($MN)
  • Table 24 Global Efficacy Testing Market Outlook, By Cosmetic Manufacturers (2024-2032) ($MN)
  • Table 25 Global Efficacy Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.